GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citi Pharma Ltd (KAR:CPHL) » Definitions » Other Current Liabilities

Citi Pharma (KAR:CPHL) Other Current Liabilities : ₨0.00 Mil (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is Citi Pharma Other Current Liabilities?

Citi Pharma's other current liabilities for the quarter that ended in . 20 was ₨0.00 Mil.


Citi Pharma Other Current Liabilities Historical Data

The historical data trend for Citi Pharma's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citi Pharma Other Current Liabilities Chart

Citi Pharma Annual Data
Trend
Other Current Liabilities

Citi Pharma Semi-Annual Data
Other Current Liabilities

Citi Pharma Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.


Citi Pharma Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Citi Pharma's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Citi Pharma Business Description

Traded in Other Exchanges
N/A
Address
588 Q Block, Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its departments include Active Pharma Ingredients (API) and Formulations. Some of its products include Askprol C Tab, Lenon Tab, Recoz Tab, Cingol Tab among others.

Citi Pharma Headlines

No Headlines